Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Frailty × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Glioblastoma 362 Brain Neoplasms 147 Glioma 140 Gliosarcoma 122 Astrocytoma 103 Central Nervous System Neoplasms 100 Oligodendroglioma 67 Melanoma 66 Neuroblastoma 39 Medulloblastoma 30 Neoplasms 28 Neoplasm Metastasis 26 Recurrence 25 Ependymoma 25 Sarcoma, Ewing 21 Sarcoma 20 Rhabdomyosarcoma 17 Diffuse Intrinsic Pontine Glioma 15 Lymphoma 14 Ovarian Neoplasms 13 Breast Neoplasms 13 Neuroendocrine Tumors 11 Choroid Plexus Neoplasms 11 Carcinoma, Non-Small-Cell Lung 11 Small Cell Lung Carcinoma 10 Lung Neoplasms 10 Osteosarcoma 9 Optic Nerve Glioma 9 Neuroectodermal Tumors, Primitive 9 Spinal Cord Neoplasms 8

Interventions

Geriatric Assessment 9 Preoperative Exercise 2 Nutritional Support 2 Exercise 2 peflavit 1 microcrystalline cellulose 1 fisetin 1 epigallocatechin gallate 1 diacetamate 1 cabozantinib 1 Tretinoin 1 Therapeutics 1 Temozolomide 1 Standard of Care 1 Restraint, Physical 1 Quercetin 1 Qigong 1 Psychosocial Intervention 1 Protons 1 Photons 1 Nutrition Assessment 1 Methods 1 Immunonutrition Diet 1 Flavonoids 1 Enhanced Recovery After Surgery 1 Dasatinib 1 Control Groups 1 Capecitabine 1 Azacitidine 1 Ascorbic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05554003 2024-11-18

MeTe

European Institute of Oncology

Phase 2 Recruiting

Frailty, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡